---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-265937"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:16:43.731784+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tempest reports Q3 net loss $3.5M, cash $7.5M; continues strategic alternatives process

## Summary
- Cash and equivalents $7.5M at Sept 30, 2025, down from $30.3M at Dec 31, 2024.
- Net loss Q3 2025: $3.5M ($0.79/share) vs $10.6M ($5.32/share) in Q3 2024.
- R&D expenses fell to $0.6M from $7.6M due to reprioritizing toward strategic alternatives.
- Company continues strategic alternatives process to maximize stockholder value.
- Expects start of TPST-1495 Phase 2 in collaboration with NCI and Cancer Prevention Clinical Trials Network.

## SEC filing metadata
- accession: 0001193125-25-265937
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312525265937/0001193125-25-265937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312525265937/tpst-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-265937
- JSON: https://secwatch.observer/filing/0001193125-25-265937.json
- Plain text: https://secwatch.observer/filing/0001193125-25-265937.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.